Moderna Announces Phase 2 Data On mRNA-4157 (V940) To Be Presented At 2023 ASCO Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Moderna announced that two abstracts on mRNA-4157 (V940), an investigational mRNA individualized neoantigen therapy, will be presented at the 2023 ASCO Annual Meeting in Chicago.
May 30, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Moderna's mRNA-4157 (V940) therapy will be presented at the 2023 ASCO Annual Meeting, potentially increasing investor interest.
The presentation of Moderna's mRNA-4157 (V940) at the 2023 ASCO Annual Meeting will likely generate interest among investors and healthcare professionals. This could lead to increased visibility for the company and its investigational therapy, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100